Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants

NCT04504435 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04504435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single (in Both Fed and Fasted States) Doses of GSK3494245 in Healthy Participants
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
September 29, 2020
Completion date
January 14, 2024
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis